Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darunavir + cobicistat + emtricitabine + tenofovir disoproxil fumarate
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination antiretroviral drug composed of four small molecule agents: **darunavir**, a protease inhibitor; **cobicistat**, a pharmacokinetic enhancer (booster) via CYP3A inhibition; **emtricitabine**, a nucleoside reverse transcriptase inhibitor (NRTI); and **tenofovir disoproxil fumarate**, a nucleotide reverse transcriptase inhibitor (NtRTI). This combination is used for the treatment of HIV-1 infection in adults and pediatric patients. Darunavir inhibits the cleavage of HIV polyproteins, preventing viral replication. Cobicistat increases the plasma concentration of darunavir by inhibiting its metabolism via CYP3A. Emtricitabine and tenofovir disoproxil fumarate block HIV reverse transcriptase, essential for viral RNA to DNA conversion. The combination helps suppress viral load and delay disease progression but is not a cure for HIV/AIDS.
- Brand names
- PrezcobixTruvada
- Other names
- DRV/c + TDF/FTCdarunavir/cobicistat + tenofovir/emtricitabineStandard Medical Therapy
02
Targets
CYP3A7 (Cytochrome P450 3A7)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on darunavir + cobicistat + emtricitabine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darunavir + cobicistat + emtricitabine + tenofovir disoproxil fumarate.